SCHEMBL1133775

SCHEMBL1133775

O=C(O)C(Cc1ccccc1)N1C(=O)/C(=C/c2ccc(-c3ccc(Cl)cc3)s2)NC1=S

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PRF1 P14222 2/20 0.49
▸ PTPN1 P18031 2/20 0.46
▸ MAPT P10636 4/20 0.44
▸ KMT2A Q03164 3/20 0.43
▸ AADAT Q8N5Z0 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ POLB P06746 2/20 0.42
▸ CTSL P07711 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ MME P08473 2/20 0.41
▸ BCL2 P10415 2/20 0.41
▸ PLA2G1B P04054 1/20 0.41
▸ ATG4B Q9Y4P1 1/20 0.41
▸ BCL2L2 Q92843 1/20 0.41
▸ BAD Q92934 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ ADAMTS5 Q9UNA0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13587022 1.00 PRF1 (0.49) PRF1PTPN1MAPTKMT2AAADAT
SCHEMBL1133776 1.00 PRF1 (0.49) PRF1PTPN1MAPTKMT2AAADAT
SCHEMBL13587033 0.91 AADAT (0.46) PRF1PTPN1MAPTKMT2AAADAT
SCHEMBL4377150 0.91 BCL2L2 (0.52) PRF1PTPN1MAPTKMT2AALDH1A1
SCHEMBL1133613 0.91 PRF1 (0.49) PRF1MAPTKMT2AALDH1A1MEN1
SCHEMBL1133612 0.91 PRF1 (0.49) PRF1MAPTKMT2AALDH1A1MEN1
SCHEMBL1133685 0.91 BCL2L2 (0.52) PRF1PTPN1MAPTKMT2AALDH1A1
SCHEMBL13587021 0.91 PRF1 (0.49) PRF1MAPTKMT2AALDH1A1MEN1
SCHEMBL13587018 0.91 BCL2L2 (0.52) PRF1PTPN1MAPTKMT2AALDH1A1
SCHEMBL4380766 0.89 BCL2 (0.42) PRF1PTPN1MAPTKMT2AAADAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2285802-B1 OXO-IMIDAZOLYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY ASTEX PHARMACEUTICALS INC (US) 2015-11-11 — — EP disclosed
US-8759384-B2 Oxo-imidazolyl compounds ASTEXPHRMACEUTICALS, INC. 2014-06-24 — — US disclosed
EP-2285802-A1 OXO-IMIDAZOLYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY SuperGen, Inc. (US) 2011-02-23 — — EP disclosed
US-20090298900-A1 Oxo-Imidazolyl Compounds ASTEXPHRMACEUTICALS, INC. 2009-12-03 — — US disclosed
WO-2009139870-A1 OXO-IMIDAZOLYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY SUPERGEN, INC. 2009-11-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298900-A1 Oxo-Imidazolyl Compounds GALE, CYP51A1, GNE PRF1 2725/4885PTPN1 3100/4885MAPT 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback